OTLK
Outlook Therapeutics, Inc.
$1.22
+10.91%
$170.9M
No data for this timeframe.
Vol
Market Cap$170.9M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (78%)
Inst. Holders24 funds
Inst. Value$851.7K
Inst. Activity4 buys / 1 sells
Insider Activity7B / 0S
Insider Net $$5.3M
Reddit Sentiment67° Warm
SEC Reports15
Press Releases5
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001649989·Prev Close $1.10
Recent Activity
Jun 5, 2026
SEC
Outlook Therapeutics resubmitted its Biologics License Application (BLA) for ONS-5010/LYTENAVA (bevacizumab-vikg) to the
8-K — Impact 7/10
Jun 5, 2026
short_volume
Short Volume: OTLK — 58.5% short (4.2M / 7.2M)
Short: 4,196,344 | Exempt: 50,731 | TRF Vol: 7,174,669 | Short Ratio: 58.5% | Off-exchange volume (d
Jun 3, 2026
SEC
A significant insider buying cluster at Outlook Therapeutics, totaling $5.25M in open-market purchases, is dominated by
CLUSTER — Impact 7/10
Jun 2, 2026
SEC
A cluster of insider purchases totaling ~$5.24M occurred at Outlook Therapeutics over the past week, dominated by a $5.0
CLUSTER — Impact 6/10
Jun 2, 2026
Insider
Haddadin Yezan Munther bought 29,000 shares
Director @ $0.8326 ($24.1K)
May 28, 2026
Insider
Sukhtian Ghiath M. disposed of 3,458,571 shares
Director
May 28, 2026
Insider
Sukhtian Ghiath M. bought 3,458,571 shares
Director
Inst.
COMMONWEALTH EQUITY SERVICES, LLC — DOUBLED
470,000 shares ($96.7K)
Price Targets
$5.50
+350.8% upside
Strong Buy
Current $1.22
Low $0.5000
Median $6.00
High $10.00
3 analysts
$0.5000
$10.00
Analyst Ratings
2Strong Buy
5Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 11, 2026 | Ascendiant Capital | MAINTAIN | Buy → Buy |
| May 18, 2026 | BTIG | DOWNGRADE | Buy → Neutral |
| Mar 11, 2026 | Ascendiant Capital | MAINTAIN | Buy → Buy |
| Feb 18, 2026 | HC Wainwright & Co. | REITERATE | Neutral → Neutral |
| Feb 18, 2026 | Chardan Capital | MAINTAIN | Neutral → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.09 ▲ +12.5% | $-0.11 — $-0.07 | 79% YoY | 3 |
| Next Q | $-0.08 ▲ +7.7% | $-0.10 — $-0.05 | 72% YoY | 3 |
| Current FY | $-0.51 ▼ -0.7% | $-0.51 — $-0.51 | 73% YoY | 1 |
| Next FY | $-0.22 ▲ +17.5% | $-0.33 — $-0.12 | 57% YoY | 3 |
Latest Reports
BULLISH
8-K
7/10
Outlook Therapeutics resubmitted its Biologics License Application (BLA) for ONS-5010/LYTENAVA (bevacizumab-vikg) to the
Jun 5, 2026
BULLISH
CLUSTER
7/10
A significant insider buying cluster at Outlook Therapeutics, totaling $5.25M in open-market purchases, is dominated by
Jun 3, 2026
BEARISH
Press
7/10
Outlook Therapeutics announces a $5.0M registered direct offering of 8.54M shares at $0.5855/share to its largest stockh
May 28, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | DOUBLED |
| VANGUARD CAPITAL MANAGEMENT LLC | $405.2K | — |
| BlackRock, Inc. | $98.3K | — |
| COMMONWEALTH EQUITY SERVICES, LLC | $96.7K | DOUBLED |
| RENAISSANCE TECHNOLOGIES LLC | $52.5K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 2, 2026 | Haddadin Yezan | BUY | $24.1K |
| May 28, 2026 | Sukhtian Ghiath | H | $0.00 |
| May 28, 2026 | Sukhtian Ghiath | BUY | $0.00 |
| May 28, 2026 | Sukhtian Ghiath | BUY | $5.0M |
| May 27, 2026 | Sukhtian Faisal | BUY | $50.0K |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
24 institutional holders with $851.7K total value (4,203,476 shares) as of 2026-Q1. Top holders: ROYAL, VANGUARD, BlackRock,. Net buying activity: 4 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 85 | $0.00 | 0.0% | DOUBLED +4725.9% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 1,967,160 | $405.2K | 47.6% | — |
| 3 | BlackRock, Inc. | 477,471 | $98.3K | 11.5% | — |
| 4 | COMMONWEALTH EQUITY SERVICES, LLC | 470,000 | $96.7K | 11.4% | DOUBLED +317.8% |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 255,157 | $52.5K | 6.2% | — |
| 6 | VANGUARD FIDUCIARY TRUST CO | 176,529 | $36.4K | 4.3% | — |
| 7 | STATE STREET CORP | 163,102 | $33.6K | 3.9% | DOUBLED +116.6% |
| 8 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 134,084 | $27.6K | 3.2% | — |
| 9 | GROUP ONE TRADING LLC | 113,701 | $23.4K | 2.7% | DOUBLED +207.3% |
| 10 | CITADEL ADVISORS LLC | 113,700 | $23.4K | 2.7% | — |
| 11 | CITADEL ADVISORS LLC | 80,800 | $16.6K | 2.0% | — |
| 12 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 42,800 | $9.0K | 1.1% | — |
| 13 | Vanguard Personalized Indexing Management, LLC | 31,492 | $6.5K | 0.8% | DOUBLED +101.8% |
| 14 | Point72 Asset Management, L.P. | 29,038 | $6.0K | 0.7% | — |
| 15 | RAYMOND JAMES FINANCIAL INC | 27,051 | $5.6K | 0.7% | — |
| 16 | PNC FINANCIAL SERVICES GROUP, INC. | 25,000 | $5.2K | 0.6% | ADD +66.7% |
| 17 | GOLDMAN SACHS GROUP INC | 10,275 | $2.1K | 0.2% | — |
| 18 | Vanguard Global Advisers, LLC | 6,907 | $1.4K | 0.2% | — |
| 19 | MORGAN STANLEY | 3,806 | $783.00 | 0.1% | TRIM -36.8% |
| 20 | JONES FINANCIAL COMPANIES LLLP | 2,500 | $520.00 | 0.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| COMMONWEALTH EQUITY SERVICES, LLC | DOUBLED | 112,500 | 470,000 | +317.8% | $96.7K | 2026-Q1 |
| GROUP ONE TRADING LLC | DOUBLED | 36,997 | 113,701 | +207.3% | $23.4K | 2026-Q1 |
| Vanguard Personalized Indexing Management, LLC | DOUBLED | 15,605 | 31,492 | +101.8% | $6.5K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | ADD | 15,000 | 25,000 | +66.7% | $5.2K | 2026-Q1 |
| MORGAN STANLEY | TRIM | 6,024 | 3,806 | -36.8% | $783.00 | 2026-Q1 |
| STATE STREET CORP | DOUBLED | 75,302 | 163,102 | +116.6% | $257.7K | 2025-Q4 |
| GROUP ONE TRADING LLC | DOUBLED | 16,833 | 36,997 | +119.8% | $58.5K | 2025-Q4 |
| PNC FINANCIAL SERVICES GROUP, INC. | ADD | 11,528 | 15,000 | +30.1% | $23.7K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 775 | 6,024 | +677.3% | $9.5K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 1,410 | 2,480 | +75.9% | $3.9K | 2025-Q4 |
| FMR LLC | DOUBLED | 106 | 606 | +471.7% | $957.00 | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 90,475 | 128 | -99.9% | $203.00 | 2025-Q4 |
| CWM, LLC | NEAR_EXIT | 9,138 | 283 | -96.9% | — | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 7,813 | 90,475 | +1058.0% | $95.9K | 2025-Q3 |
| GROUP ONE TRADING LLC | TRIM | 27,304 | 16,833 | -38.3% | $17.8K | 2025-Q3 |
| Russell Investments Group, Ltd. | TRIM | 24,477 | 15,498 | -36.7% | $16.4K | 2025-Q3 |
| MORGAN STANLEY | NEAR_EXIT | 425,599 | 775 | -99.8% | $821.00 | 2025-Q3 |
| COMMONWEALTH EQUITY SERVICES, LLC | DOUBLED | 28,151 | 113,151 | +301.9% | $120.00 | 2025-Q3 |
| FMR LLC | NEAR_EXIT | 170,502 | 106 | -99.9% | $112.00 | 2025-Q3 |
| BARCLAYS PLC | NEAR_EXIT | 101 | 1 | -99.0% | $1.00 | 2025-Q3 |
| BARCLAYS PLC | NEAR_EXIT | 17,040 | 101 | -99.4% | — | 2025-Q2 |
| VANGUARD GROUP INC | ADD | 837,407 | 1,251,598 | +49.5% | $2.0M | 2025-Q2 |
| STATE STREET CORP | TRIM | 288,260 | 85,452 | -70.4% | $136.7K | 2025-Q2 |
| UBS Group AG | TRIM | 94,603 | 55,124 | -41.7% | $88.2K | 2025-Q2 |
| Russell Investments Group, Ltd. | DOUBLED | 2,536 | 24,477 | +865.2% | $39.2K | 2025-Q2 |
5 unique insiders with 8 transactions. Net insider value: $5.3M ($5.3M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | Haddadin Yezan Munther | Director | BUY | 29,000 | $0.8326 | $24.1K |
| May 28, 2026 | Sukhtian Ghiath M. | Director | H | 3,458,571 | — | — |
| May 28, 2026 | Sukhtian Ghiath M. | Director | BUY | 3,458,571 | — | — |
| May 28, 2026 | Sukhtian Ghiath M. | Director | BUY | 8,539,709 | $0.5855 | $5.0M |
| May 27, 2026 | Sukhtian Faisal Ghiath | Director | BUY | 122,174 | $0.4093 | $50.0K |
| May 26, 2026 | THURMAN RANDY H | Director | BUY | 5,000 | $0.4290 | $2.1K |
| May 26, 2026 | HILZINGER KURT J | Director | BUY | 400,000 | $0.4413 | $176.5K |
| May 26, 2026 | Haddadin Yezan Munther | Director | BUY | 34,000 | $0.4400 | $15.0K |
15 SEC filing reports analyzed. Sentiment: 3 bullish, 7 bearish, 1 mixed, 4 neutral. Avg impact: 5.8/10.
BULLISH
8-K
7/10
Outlook Therapeutics resubmitted its Biologics License Application (BLA) for ONS-5010/LYTENAVA (beva
Jun 5, 2026
BULLISH
CLUSTER
7/10
A significant insider buying cluster at Outlook Therapeutics, totaling $5.25M in open-market purchas
Jun 3, 2026
MIXED
CLUSTER
6/10
A cluster of insider purchases totaling ~$5.24M occurred at Outlook Therapeutics over the past week,
Jun 2, 2026
BEARISH
DEFA14A
6/10
Outlook Therapeutics filed DEFA14A definitive additional proxy materials for its July 16, 2026 Speci
Jun 1, 2026
BEARISH
8-K
6/10
Outlook Therapeutics filed an 8-K disclosing a registered direct offering of 8,539,709 shares of com
May 29, 2026
BEARISH
424B5
7/10
Outlook Therapeutics is issuing 8,539,709 shares of common stock at $0.5855 per share to a single ac
May 29, 2026
BEARISH
8-K
7/10
Outlook Therapeutics entered into a securities purchase agreement for a registered direct offering o
May 28, 2026
BULLISH
CLUSTER
5/10
Two directors at Outlook Therapeutics made open-market purchases totaling ~$179K on May 26, 2026, ju
May 27, 2026
BEARISH
PRESS-RELEASE
6/10
Outlook Therapeutics reported Q2 FY2026 results with GAAP net loss of $0.05/share (vs consensus $-0.
May 15, 2026
BEARISH
424B5
7/10
Outlook Therapeutics is raising $4.65 million through a registered offering of 16.1 million shares a
Apr 23, 2026
NEUTRAL
8-K
4/10
Outlook Therapeutics completed a Federal Dispute Resolution (FDR) meeting with the FDA to appeal a C
Apr 21, 2026
NEUTRAL
8-K
4/10
Outlook Therapeutics submitted a formal dispute resolution request to the FDA regarding a Complete R
Apr 7, 2026
BEARISH
424B5
7/10
Outlook Therapeutics is conducting a $5 million public offering of 20 million shares of common stock
Mar 26, 2026
NEUTRAL
8-K
4/10
Analysis based on filing metadata only — document content was unavailable. The filing reports a depa
Mar 11, 2026
NEUTRAL
8-K
4/10
Outlook Therapeutics held a Type A meeting with the FDA to discuss the Complete Response Letter for
Mar 5, 2026
BEARISH
7/10
Outlook Therapeutics announces a $5.0M registered direct offering of 8.54M shares at $0.5855/share t
May 28, 2026
BULLISH
8/10
Outlook Therapeutics announced that the FDA granted its Formal Dispute Resolution appeal, concluding
May 26, 2026
BEARISH
6/10
Outlook Therapeutics raised approximately $5.0 million through a registered direct offering of 16.1
Apr 23, 2026
NEUTRAL
5/10
Outlook Therapeutics (OTLK) closed a public offering of 20 million shares and accompanying warrants
Mar 25, 2026
BEARISH
6/10
Outlook Therapeutics announced a best-efforts public offering of common stock or pre-funded warrants
Mar 23, 2026
Current analyst consensus: Buy (78% buy). Based on 9 analysts: 2 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.50 mean target
+350.8% upside
Strong Buy (2.00)
$0.5000 Low
$10.00 High
| Metric | Value |
|---|---|
| Current Price | $1.22 |
| Target Low | $0.5000 |
| Target Mean | $5.50 |
| Target Median | $6.00 |
| Target High | $10.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (2.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.09 | $-0.11 | $-0.07 | 78.8% | +12.5% | 1↑ 0↓ | $0.0B | -66.8% | 3 |
| Next Q 2026-09-30 |
$-0.08 | $-0.10 | $-0.05 | 72.4% | +7.7% | 1↑ 0↓ | $0.0B | — | 3 |
| Current FY 2026-09-30 |
$-0.51 | $-0.51 | $-0.51 | 73.1% | -0.7% | 1↑ 0↓ | $0.0B | -15.1% | 1 |
| Next FY 2027-09-30 |
$-0.22 | $-0.33 | $-0.12 | 56.9% | +17.5% | — | $0.0B | 3710.6% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.093 | |
| 7d ago | $-0.107 | +0.013 |
| 30d ago | $-0.107 | +0.013 |
| 60d ago | $-0.113 | +0.020 |
| 90d ago | $-0.140 | +0.047 |
4 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 11, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
| May 18, 2026 | BTIG | DOWNGRADE | Buy | Neutral |
| Mar 11, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
| Feb 18, 2026 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Feb 18, 2026 | Chardan Capital | MAINTAIN | Neutral | Neutral |
| Jan 5, 2026 | Chardan Capital | MAINTAIN | Neutral | Neutral |
| Jan 2, 2026 | HC Wainwright & Co. | MAINTAIN | Neutral | Neutral |
| Dec 22, 2025 | Ascendiant Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| May 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Apr 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Mar 1, 2026 | 2 | 5 | 3 | 0 | 0 | 70% | |
| Feb 1, 2026 | 2 | 5 | 3 | 0 | 0 | 70% | |
| Jan 1, 2026 | 2 | 5 | 4 | 0 | 0 | 64% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
5 mentions
3 bullish
0 bearish
5 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 10, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Jun 10, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Jun 6, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 6, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 28, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
OTLK - Good Potential
▲ 1
💬 0
⚡ 0.5
OTLK! Is my math wrong?
▲ 1
💬 1
⚡ 0.5
Jun 5, 2026
short_volume
Short Volume: OTLK — 58.5% short (4.2M / 7.2M)
Short: 4,196,344 | Exempt: 50,731 | TRF Vol: 7,174,669 | Short Ratio: 58.5% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
other
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
<p align="justify">ISELIN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LaA08SCErPilWM8O6jp1LSp2ts7LK
May 28, 2026
activist
Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
<p align="justify">ISELIN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=n6BjhMS1GWlp7Pqr42Rm7kWQTaEor5
May 27, 2026
short_volume
Short Volume: OTLK — 56.0% short (25.0M / 44.8M)
Short: 25,049,160 | Exempt: 358,121 | TRF Vol: 44,753,390 | Short Ratio: 56.0% | Off-exchange volume (dark pool + OTC)
May 26, 2026
fda
Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Company plans to resubmit BLA to the FDA in June 2026 <pre>Company plans to resubmit BLA to the FDA in June 2026</pre>
May 26, 2026
short_volume
Short Volume: OTLK — 57.2% short (63.1M / 110.3M)
Short: 63,098,866 | Exempt: 431,648 | TRF Vol: 110,283,817 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: OTLK — 57.5% short (5.8M / 10.0M)
Short: 5,758,476 | Exempt: 38,122 | TRF Vol: 10,018,032 | Short Ratio: 57.5% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: OTLK — 56.9% short (0.7M / 1.3M)
Short: 726,788 | Exempt: 0 | TRF Vol: 1,277,317 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
May 15, 2026
earnings
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
<p align="justify">ISELIN, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=sKsQ_GgeOye69G5LKtDKVcCqtz7tz7
May 15, 2026
short_volume
Short Volume: OTLK — 63.5% short (0.8M / 1.3M)
Short: 815,255 | Exempt: 3,100 | TRF Vol: 1,283,774 | Short Ratio: 63.5% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: OTLK — 66.9% short (1.4M / 2.0M)
Short: 1,368,348 | Exempt: 11,300 | TRF Vol: 2,044,654 | Short Ratio: 66.9% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings_calendar
OTLK Q2 2026 Earnings Scheduled — 2026-05-13
May 6, 2026
short_volume
Short Volume: OTLK — 57.9% short (3.1M / 5.3M)
Short: 3,069,707 | Exempt: 0 | TRF Vol: 5,302,835 | Short Ratio: 57.9% | Off-exchange volume (dark pool + OTC)
May 5, 2026
short_volume
Short Volume: OTLK — 59.4% short (2.3M / 3.9M)
Short: 2,297,492 | Exempt: 0 | TRF Vol: 3,869,919 | Short Ratio: 59.4% | Off-exchange volume (dark pool + OTC)
May 4, 2026
short_volume
Short Volume: OTLK — 55.7% short (1.2M / 2.2M)
Short: 1,238,835 | Exempt: 12,201 | TRF Vol: 2,224,870 | Short Ratio: 55.7% | Off-exchange volume (dark pool + OTC)